What are the detailed pharmacokinetic characteristics of quetiapine (Seroquel)?

Pharmacokinetics of Quetiapine

Quetiapine demonstrates rapid oral absorption with peak concentrations at 1.5 hours, extensive hepatic metabolism primarily via CYP3A4, high protein binding (83%), and a terminal half-life of approximately 6-7 hours, with steady-state achieved within 2 days of dosing. 1

Absorption

Quetiapine is rapidly absorbed after oral administration:

• Time to peak concentration (Tmax): 1-2 hours 1, 2
• Bioavailability: The tablet formulation is 100% bioavailable relative to solution 1
• Food effect: Marginally affected by food administration
  • High-fat meals increase Cmax by 25% and AUC by 15% 1
  • Light meals have no significant effect 3
  • Can be administered without regard to meals in clinical practice

Distribution

• Volume of distribution (Vd): 10±4 L/kg, indicating wide distribution throughout the body 1
• Protein binding: 83% bound to plasma proteins at therapeutic concentrations 1
• CNS penetration: Achieves 10-40 times higher concentrations in brain tissue compared to blood 4
• Drug interactions: Does not affect binding of warfarin or diazepam to serum albumin, and vice versa 1

Metabolism

Quetiapine undergoes extensive hepatic metabolism with less than 1% excreted unchanged 1:

• Primary enzyme: CYP3A4 is the predominant isoenzyme responsible for metabolism 1, 2

• Metabolic pathways:

  • Sulfoxidation to sulfoxide metabolite (inactive)
  • Oxidation to parent acid metabolite (inactive)
  • Formation of N-desalkyl quetiapine (norquetiapine) - the active metabolite 1

• Active metabolite (norquetiapine):

  • Has similar activity at D2 receptors but greater activity at 5HT2A receptors than parent drug 1
  • Circulates at 2-12% of quetiapine concentration 2
  • Metabolite-to-parent ratio approximately 0.5 5
  • Half-life approximately 18 hours (longer than parent drug) 5

• First-pass metabolism: High, with systemic availability of 10-70% 4

Elimination

• Primary route: Hepatic metabolism 1
• Excretion:
  • 73% recovered in urine 1
  • 20% recovered in feces 1
• Terminal half-life: 6-7 hours for quetiapine 1, 5
• Steady-state: Achieved within 2 days of dosing 1
• Renal excretion: Low; renal impairment has minimal effect on pharmacokinetics 4, 2

Dose Proportionality

Quetiapine exhibits linear pharmacokinetics within the clinical dose range 1, 5:

• Multiple-dose pharmacokinetics are dose-proportional
• Accumulation is predictable upon multiple dosing
• This linearity holds across the range of 300-800 mg doses 5

Special Populations

Elderly Patients

• Oral clearance reduced by 40% in patients ≥65 years compared to younger patients 1
• Dose adjustment necessary in elderly populations 6
• Reduce dose in older patients and those with hepatic impairment 6

Pediatric Patients (10-17 years)

When adjusted for dose and weight 1:

• Parent compound: AUC and Cmax 41% and 39% lower than adults
• Norquetiapine metabolite: AUC and Cmax 45% and 31% higher than adults
• At steady state, unadjusted pharmacokinetics similar to adults

Hepatic Impairment

• Oral clearance reduced in patients with hepatic dysfunction 1
• Dose reduction required 6
• Important effect on hepatic elimination given extensive hepatic metabolism 4

Renal Impairment

• No significant effect on quetiapine pharmacokinetics 2
• Dose adjustment generally not required

Drug Interactions

CYP3A4 Inducers

Strong and moderate CYP3A4 inducers dramatically increase quetiapine clearance 7:

• Increase apparent clearance approximately 4-fold 7
• Phenytoin and thioridazine increase quetiapine clearance 2
• Carbamazepine: Can reduce quetiapine to undetectable levels; induction effect lasts at least 3 weeks after carbamazepine withdrawal 8
• Dose adjustment necessary when co-administered with potent CYP3A4 inducers

CYP3A4 Inhibitors

• Strong CYP3A4 inhibitors reduce clearance by 93% 7
• Ketoconazole decreases quetiapine clearance 2
• Avoid concurrent administration or adjust dose based on therapeutic drug monitoring 7

No Significant Interactions

• Cimetidine, haloperidol, risperidone, imipramine: No clinically significant effects 2
• Lithium: No effect on serum lithium concentration 2
• Does not interfere with metabolism of drugs metabolized by CYP450 enzymes 1

Formulation Differences

Immediate-Release (IR) vs Extended-Release (XR)

• IR absorption rate constant: 1.46 h⁻¹ 9
• XR absorption rate constant: 0.10 h⁻¹ 9
• XR provides similar AUC and Cmin with slightly lower Cmax compared to equivalent twice-daily IR dosing 3
• XR exhibits less variable exposure (coefficient of variation 39.2% vs 51.2% for IR) 3
• XR reaches steady state after 3 days of sequential dosing 5

Clinical Implications

Key pharmacokinetic considerations for clinical practice:

• Steady-state timing: Therapeutic drug monitoring should occur after 2 days of consistent dosing
• CYP3A4 interactions: Avoid strong inducers/inhibitors; if unavoidable, use therapeutic drug monitoring to guide dose adjustments 7
• Elderly dosing: Start with lower doses due to 40% reduction in clearance 1
• Hepatic impairment: Requires dose reduction 6
• Renal impairment: No dose adjustment needed 2
• Carbamazepine washout: Allow minimum 3-week washout period before initiating quetiapine to avoid subtherapeutic levels 8